Cytokine release syndrome and cancer immunotherapies – historical challenges and promising futures
Cancer is the leading cause of death worldwide. Cancer immunotherapy involves reinvigorating the patient’s own immune system to fight against cancer. While novel approaches like Chimeric Antigen Receptor (CAR) T cells, bispecific T cell engagers, and immune checkpoint inhibitors have shown promising...
Main Authors: | Deep Shah, Brian Soper, Lindsay Shopland |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-05-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1190379/full |
Similar Items
-
Emerging Immunotherapy Approaches for Treating Prostate Cancer
by: Lingbin Meng, et al.
Published: (2023-09-01) -
Promise and Challenges of T Cell Immunotherapy for Osteosarcoma
by: Jeong A Park, et al.
Published: (2023-08-01) -
Cancer Immunotherapy: Where Next?
by: Walter Bodmer, et al.
Published: (2023-04-01) -
T-cell Redirecting Therapies for the Treatment of B-cell Lymphomas: Recent Advances
by: Ondine Messéant, et al.
Published: (2021-08-01) -
Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy
by: Puri Ferreros, et al.
Published: (2022-07-01)